Related Experiment Video
Updated: Aug 18, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
IgA nephropathy pathogenesis and therapy: Review & updates
Elmukhtar Habas1, Elrazi Ali2, Khalifa Farfar3
1Hamad General Medicine, Doha, Qatar.
IgA nephropathy (IgAN) is a common kidney disease. Proteinuria helps monitor IgAN progression and treatment effectiveness, with steroids as a primary therapy.
Area of Science:
- Nephrology
- Immunology
Background:
- IgA nephropathy (IgAN) is the most common primary glomerulonephritis.
- It is a leading cause of end-stage renal disease, often presenting with hematuria.
- Pathogenesis involves multifactorial autoimmune complex formation and inflammation.
Purpose of the Study:
- To review current data and clinical updates on IgA nephropathy pathogenesis.
- To explore various treatment strategies for IgAN.
Main Methods:
- Comprehensive literature search across major scientific databases (PubMed, Google Scholar, Scopus, EMBASE).
- Non-systematic clinical review of available data and clinical updates.
Main Results:
- IgAN exhibits heterogeneous global patterns, complicating pathogenesis and treatment understanding.
- Proteinuria is the key indicator for monitoring IgAN progression and treatment response.
- Steroids are foundational, supplemented by other agents with variable efficacy.
Conclusions:
- Effective IgAN management necessitates a collaborative approach between patients and physicians.
- Kidney transplantation is recommended for IgAN patients, despite high recurrence rates.
- Proteinuria monitoring is crucial for guiding IgAN treatment and assessing outcomes.
More Related Videos
Related Concept Videos
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology

